Global Clinical Oncology Next Generation Sequencing Market Size & Outlook
Global clinical oncology next generation sequencing market, 2021-2033 (US$M)
Related Markets
Global clinical oncology next generation sequencing market highlights
- The global clinical oncology next generation sequencing market generated a revenue of USD 482.3 million in 2024 and is expected to reach USD 1,930.2 million by 2033.
- The market is expected to grow at a CAGR (2025 - 2033) of 16.8% by 2033.
- In terms of segment, targeted sequencing and resequencing accounted for a revenue of USD 356.1 million in 2024.
- Whole Genome Sequencing is the most lucrative technology segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2024.
- Country-wise, China is expected to register the highest CAGR from 2025 to 2033.
Global data book summary
| Market revenue in 2024 | USD 482.3 million |
| Market revenue in 2033 | USD 1,930.2 million |
| Growth rate | 16.8% (CAGR from 2025 to 2033) |
| Largest segment | Targeted sequencing and resequencing |
| Fastest growing segment | Whole Genome Sequencing |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Whole Exome Sequencing, Targeted Sequencing and Resequencing, Whole Genome Sequencing |
Other key industry trends
- In terms of revenue, the North America accounted for 44.0% of the global clinical oncology next generation sequencing market in 2024.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2033.
- By country, China is the fastest growing regional market and is projected to reach USD 159.7 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Clinical Oncology Next Generation Sequencing Market Scope
Clinical Oncology Next Generation Sequencing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Oxford Nanopore Technologies PLC | View profile | 1133 | Edmund Halley Road, Gosling Building, Oxford Science Park, Oxford, Oxfordshire, United Kingdom, OX4 4DQ | https://www.nanoporetech.com |
| Pacific Biosciences of California Inc | View profile | 796 | 1305 O’Brien Drive, Menlo Park, CA, United States, 94025 | https://www.pacb.com |
| PerkinElmer | View profile | 10001+ | Waltham, Massachusetts, United States, North America | http://www.perkinelmer.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | http://www.roche.com |
| Paradigm Healthcare | View profile | 11-50 | San Francisco, California, United States, North America | https://paradigm-healthcare.com |
| Myriad Genetics Inc | View profile | 2700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | https://www.myriad.com |
| Eurofins Scientific SE | View profile | 61798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | https://www.eurofins.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Agilent Technologies Inc | View profile | 17700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | https://www.agilent.com |
| Illumina Inc | View profile | 9300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | https://www.illumina.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
Global clinical oncology next generation sequencing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to clinical oncology next generation sequencing market will help companies and investors design strategic landscapes.
Targeted sequencing and resequencing was the largest segment with a revenue share of 73.83% in 2024. Horizon Databook has segmented the Global clinical oncology next generation sequencing market based on whole exome sequencing, targeted sequencing and resequencing, whole genome sequencing covering the revenue growth of each sub-segment from 2021 to 2033.
- Global Clinical Oncology Next Generation Sequencing Technology Outlook (Revenue, USD Million, 2021-2033)
- Whole Genome Sequencing
- Targeted Sequencing and Resequencing
- Whole Exome Sequencing
- Global Clinical Oncology Next Generation Sequencing Workflow Outlook (Revenue, USD Million, 2021-2033)
- NGS Data Analysis
- NGS Pre-Sequencing
- NGS Sequencing
- Global Clinical Oncology Next Generation Sequencing Application Outlook (Revenue, USD Million, 2021-2033)
- Screening
- Sporadic Cancer
- Inherited Cancer
- Companion Diagnostics
- Others
- Screening
- Global Clinical Oncology Next Generation Sequencing End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Clinics
- Laboratories
Reasons to subscribe to Global clinical oncology next generation sequencing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global clinical oncology next generation sequencing market databook
-
Our clientele includes a mix of clinical oncology next generation sequencing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global clinical oncology next generation sequencing market, including forecasts for subscribers. This global databook contains high-level insights into Global clinical oncology next generation sequencing market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Global clinical oncology next generation sequencing ngs market size, by regions, 2021-2033 (US$M)
Top 10 countries: Clinical oncology next generation sequencing ngs market size, 2024 (US$M)
Global clinical oncology next generation sequencing ngs market share, by workflow, 2024 & 2033 (%, US$M)
Clinical oncology next generation sequencing market: Opportunity assessment by country
Global clinical oncology next generation sequencing market, by region, 2024 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
